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Entecavir and tenofovir disoproxil fumarate are potent and effective antiviral drugs that now represent recommended treatment options for chronic HBV infection. However, no or very limited clinical evidence is currently available on these drugs for the management of HBV reactivation in patients with haematological malignancies.
Herein, we report a case of HBV reactivation in a patient with non-Hodgkin's lymphoma following a rituximabbased regimen, and who was successfully treated with a combination antiviral treatment including entecavir and tenofovir disoproxil fumarate.
HBV reactivation represents a serious cause of liverrelated morbidity and mortality in patients with haematological malignancies undergoing cytotoxic or immunosuppressive chemotherapy [1, 2] . The risk of HBV reactivation is heightened by the use of newer therapeutic monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52) that cause profound and long-lasting immunosuppression [3] [4] [5] . All candidates for chemotherapy and immunosuppressive therapy should be screened for hepatitis B surface antigen (HBsAg) and antibodies against hepatitis B core antigen (anti-HBc) and surface antigen (anti-HBs) prior to initiation of treatment [6] [7] [8] . The most commonly used antiviral drug in HBV reactivation is lamivudine. However, prognosis of patients undergoing a chemotherapeutic regimen including rituximab remains severe despite lamivudine therapy. Furthermore, lamivudine efficiency is hampered by the high rate of emergence of drug resistance mutations within HBV polymerase, which are associated with treatment failure [9] . Considering the high rate of mortality associated with HBV reactivation during rituximab therapy, the use of more potent and effective antiviral drugs needs to be evaluated. Entecavir and tenofovir disoproxil fumarate are potent and effective antiviral drugs that now represent appropriate treatment options for chronic HBV infection. However, no or very limited clinical evidence is currently available on these drugs for the management of HBV reactivation in patients with haematological malignancies [10] . Here, we report a case of HBV reactivation in a patient with non-Hodgkin's lymphoma following a rituximab-based regimen, who was successfully treated with a combination antiviral treatment including entecavir and tenofovir disoproxil fumarate.
A [11] . Serum HBV DNA was extracted using a commercially available kit (QIAamp DNA Blood Mini Kit; Qiagen, Inc., Chatsworth, CA, USA). HBV sequencing was performed on the automated ABI Prism ® 3100 Genetic Analyzer using the BigDye ® Terminator Cycle Sequencing Kit (Applied Biosystems, Warrington, UK). To define HBV genotype, sequences were compared with ≥30 GenBank reference sequences. There was also evidence of a decrease of white blood cells associated with neutropaenia (neutrophil count 0.43×10 9 cells/l). Rituximab therapy was interrupted and antiviral treatment with entecavir (0.5 mg/daily) was immediately started. After 15 days of antiviral treatment, there was a progressive decrease of liver enzymes with normalization within 2 months. Serum HBV DNA levels promptly decreased following introduction of entecavir; in particular, levels of HBV DNA were 114,000 IU/ml and 4,930 IU/ml after 1 and 4 months of treatment, respectively. In May 2009, the patient had two episodes of febrile neutropaenia associated with development of oral ulcers and pneumonia that resolved with antimicrobial treatment and cycles of granulocyte colony-stimulating factor. After 7 months of entecavir treatment, the patient again showed an increase in transaminase levels (AST 132 IU/l and ALT 186 IU/l) with viral rebound (HBV DNA 80,000 IU/ml). The antiviral treatment was well tolerated and no evidence of inadequate adherence was detected. A new genotypic test was performed and no mutations conferring drug resistance were detected at the polymerase gene. The molecular analysis of the surface gene, which includes the main immunodominant epitope 'a' region, showed the following changes: G10R, S31N, Q101R, T118A, G130R and R169H. Considering the persistence of detectable HBV viraemia and severe neutropaenia, antiviral treatment was intensified both by adding tenofovir disoproxil fumarate (300 mg/daily) and by increasing the dose of entecavir to 1 mg. After 2 weeks of treatment, the patient presented a normalization of liver enzymes and HBV DNA levels were undetectable. After 5 months, the patient was asymptomatic and the combined antiviral treatment was well tolerated. Lactic acid and HCO 3 levels were within normal ranges. Laboratory analyses showed normal ALT, undetectable HBV DNA, positivity for HBsAg and HBeAg and a neutrophil count of 2.4×10 9 cells/l. Figure 1 shows changes observed in HBV DNA and liver enzymes.
A greater understanding of the immune-mediated pathogenesis of HBV, as well as considerable improvements in antiviral treatments, have led to much progress in the management of HBV reactivation, an important clinical problem. In particular, the early identification of high-risk individuals before anticancer treatment is crucial, and it is mandatory to start antiviral drugs immediately upon HBV reactivation before the onset of hepatitis. Common therapeutic strategies for HBV reactivation include the use of nucleoside/nucleotide analogues, such as lamivudine and adefovir dipivoxil. Entecavir, telbivudine, and tenofovir disoproxil fumarate were recently introduced in clinical practice for the management of chronic HBV infection, but little is known about the use of these drugs in monotherapy or in combination for haematological patients undergoing intensive immunosuppressive therapy [12] .
The present case, to our knowledge, is the first report of successful combined use of entecavir plus tenofovir disoproxil fumarate in the management of HBV reactivation following rituximab-based chemotherapy for haematological malignancy. During rituximab maintenance treatment, the patient developed HBV reactivation associated with a persistent neutropaenia, although her baseline HBV serology was only positive for anti-HBc and anti-HBs and HBV DNA was undetectable. According to the European Association for the Study of the Liver guidelines [13] , no antiviral prophylaxis had been given, but a close monitoring of virological and hepatic parameters was carried out. Antiviral treatment with entecavir was promptly initiated when the patient had an increase in liver enzymes or HBV DNA levels, without symptoms or signs of jaundice and liver decompensation. After a rapid and marked reduction of viral replication associated with a progressive normalization of transaminases, the patient again presented an increase in HBV DNA and liver enzymes. The lack of drug resistance mutations at genotypic analysis indicates that the use of an antiviral drug with a high genetic barrier, such as entecavir, might be crucial in avoiding viral evolution. It is conceivable that a partial virological response associated with the subsequent biochemical breakthrough is related to the persistent and severe immune impairment of T-and B-cell function [14] . In this respect, lymphocyte depletion after anti-CD20 therapy was crucial in causing the lack of immune control of HBV. Viral rebound has also been well described in patients with chronic hepatitis C who received anti-CD20 for the treatment of cryoglobulinaemia [15] . In the present case, it is interesting to note the strict temporal association between the appearance of neutropaenia and the reactivation of hepatitis, and the reversal of neutropaenia concurrent with the disappearance of HBV DNA. Although we cannot rule out the effect of previous fludarabine treatment, a possible pathogenetic correlation between neutropaenia and viral replication should be taken into consideration. Cases of isolated neutropaenia without changes in erythrocytes and platelet counts have already been reported to be associated with acute hepatitis. The mechanism by which HBV might induce neutropaenia is not clear, but an effective antiviral therapy might reverse neutropaenia [16] . In addition, it is likely that the decrease of neutrophils might explain the low level of liver inflammation seen in our patient, who never had high values of transaminases. In two recent case reports, entecavir was successfully used as a first-line treatment for HBV reactivation following chemotherapy containing rituximab [17, 18] . In the present case, we obtained full viral suppression and stable normalization of liver enzymes after starting a combination strategy including entecavir plus tenofovir disoproxil fumarate. Monotherapy with either of these latest-generation anti-HBV agents represents the current preferred strategy in treatment-naive patients. However, some experts suggest a treatment modification for patients who have a suboptimal virological response after 1 year of therapy [13] . In the present case, the persistent state of immunosuppression associated with the potential risk of a severe hepatitis flare was the main reason for the use of a combination therapy including potent inhibitors of HBV replication, such as entecavir and tenofovir disoproxil fumarate. Although anti-HBV combination therapy has been considered in patients with decompensated cirrhosis and following liver transplantation, studies examining the safety and efficacy of such strategies in the management of HBV reactivation following chemotherapy for haematological malignancy should be strongly encouraged.
